Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Intramuscular H5N1 Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly
2010-019835-37Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2010
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of inactivated Vero cell based whole virus influenza A/H5N1 in Influenza A H5N1 infection (H5N1) (2 arms), sponsored by Sanofi. Primary endpoints: Safety and Immunogenicity. Started May 2010; status: completed.
02
Drugs
inactivated Vero cell based whole virus influenza A/H5N1
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on 2010-019835-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019835-37.